Phase III IMpower131 Study Showed Genentechs TECENTRIQ Atezolizumab Plus Chemotherapy Carboplatin and ABRAXANE Reduced the Risk of Disease Worsening or Death for People with Advanced Squamous NonSmall Cell Lung Cancer

Data will be featured in the ASCO press program on Saturday June 2 and presented at ASCO on Monday June 4 Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that results from the Phase III IMpower131 ...